Elaine Sunderlin, MD
Endocrinology, Diabetes & Metabolism · Mooresville, NCNPI 1780844621
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $276,294 of the $319,743 with a category attached, or 86.4%. Novo Nordisk accounts for 92.7% of it on its own, with 56 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 951 payments — averaging $336.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$296K
- AstraZeneca$8K
- Cequr Corporation$5K
- Amgen$2K
- Lilly USA, LLC$1K
- Johnson & Johnson$564
- plus $7K from 51 others
What the payments were for
- Speaking & faculty fees$276,29486%
- Travel & lodging$23,8037%
- Food & beverage$19,5486%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$319,743 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $698,271 |
| OzempicSemaglutide | 398 | $558,646 |
| JardianceEmpagliflozin | 211 | $250,382 |
| MounjaroTirzepatide | 125 | $172,534 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 116 | $156,048 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $105,292 |
| TrulicityDulaglutide | 69 | $85,824 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $83,132 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $59,336 |
| FarxigaDapagliflozin Propanediol | 43 | $54,801 |
| RybelsusSemaglutide | 28 | $44,411 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 29 | $36,381 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 46 | $36,221 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 23 | $26,965 |
| Novolog FlexpenInsulin Aspart | 75 | $22,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $112 | $698,27114 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $296,309 | $614,258469 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $1,182 | $281,372287 claims |
| Boehringer IngelheimJardiance | $490 | $250,382211 claims |
| AstraZenecaFarxiga | $7,616 | $54,80143 claims |
| Cequr CorporationCequr Simplicity | $5,128 | $26,96523 claims |
| MerckJanuvia | $79 | $17,08218 claims |
| AbbVieSynthroid | $297 | $7,36272 claims |
| IBSA Pharma Inc.Tirosint-Sol | $492 | $4,10216 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $318 | $4,088297 claims |
| Sanofi-aventis U.S. LLCLantus | $524 | $3,55022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Mooresville
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.